Clinical trials: Libido Disorder
Sexual Dysfunctions, Psychological
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
- Trial name
- NCT00601367
- Testing
- flibanserin flexible dose
- Where
- 68 sites in Austria, Belgium and 10 more
- Volunteers
- 480 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunction, Physiological, Body Image
Women's Interventions for Sexual Health: WISH
The overall objective of this program of research is to improve sexual health outcomes for women diagnosed with breast cancer. Our team is developing a multi-component intervention for the four key predictors of sexual health in…
- Conditions
- Sexual Dysfunction, Physiological, Body Image, Libido; Loss, Aversion
- Trial name
- WISH (NCT05692960)
- Testing
- Hypnotic Relaxation Intervention (HRI), Vulvovaginal Atrophy (VVA)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Tennessee, Knoxville
Hypoactive Sexual Desire Disorder
Effects of Flibanserin on the Pre- and Post-menopausal Female Brain
The purpose of the present study is to understand the neurobiological mechanisms of action underlying sexual desire building on prior work Dr. Stephanie Cacioppo has done in which desire was not manipulated.
- Trial name
- NCT02770768
- Testing
- Flibanserin
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Chicago
Contraception, Libido
Effects of SH T00658ID on Libido
The aim of the study is to investigate whether women on oral contraceptives (OCs) suffering from acquired OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year will express the same level…
- Trial name
- NCT00764881
- Testing
- EV/DNG (Qlaira, BAY86-5027, SH T00658ID), Microgynon
- Where
- 32 sites in Australia, Austria and 5 more
- Volunteers
- 217 people
- Sponsor
- Bayer
Sexual Dysfunctions, Psychological
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
- Trial name
- NCT01188603
- Testing
- flibanserin 100 mg dose every evening
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder
To generate additional long-term safety and efficacy data on flibanserin in premenopausal women and establish long-term safety and tolerability of flibanserin in naturally postmenopausal women with Hypoactive Sexual Desire…
- Trial name
- NCT01103362
- Testing
- flibanserin
- Where
- 95 sites in United States, Canada
- Volunteers
- 596 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Breast Carcinoma, Cervical Carcinoma
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer.
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal
- Trial name
- NCT03180294
- Testing
- Bupropion 150 mg XL
- Where
- 362 sites in United States
- Volunteers
- 230 people
- Sponsor
- NRG Oncology
Hypoactive Sexual Desire Disorder, Sexual Dysfunction
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
The overall aim of this research is to adapt and pilot test a multi-component, mindfulness-based behavioral intervention for women age 50 and older with low sexual desire.
- Conditions
- Hypoactive Sexual Desire Disorder, Sexual Dysfunction, Female Sexual Dysfunction
- Trial name
- NCT03232801
- Testing
- mindfulness-based multicomponent intervention, general health education group
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Pittsburgh
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT00996372
- Testing
- flibanserin
- Where
- 75 sites in United States
- Volunteers
- 949 people
- Sponsor
- Sprout Pharmaceuticals, Inc